Activity of Thiopeptide Antibiotic Nocathiacin against Gram -Positive Bacteria

Rui-xue LV,Xiang-dong CHEN,Hui WANG,Jian-wei JIANG,Shan SU
DOI: https://doi.org/10.13664/j.cnki.pcr.2014.04.036
2014-01-01
Abstract:To investigate the activity of a novel thiopeptide antibiotic nocathiacin against clinically isolated Gram-positive bacteria comparing with those commonly used antibiotics. Methods: MIC (Minimal Inhibitory Concentration) was determined by a two - fold agar dilution method. MBC (Minimal Bactericidal Concentration) was determined by a micro-broth dilution method. ED50 was determined by an infection-protection method. Results: Nocathiacin showed strong activities against MRSA and PRSP. MIC50 against MRSA, MSSA, MRSE, MSSE, PRSP/PISP, Streptococcus pyogenes, Enterococcus were 0.016, 0.016, 0.0625, 0.03125, 0.008, 0.008, 0.016 mg·L-1, respectively. Its MIC50 was 1/32~1/128 of vancomycin, 1/4~1/256 of moxifloxacin and 1/32~1/256 of linezolid, respectively. After intravenous injection, nocathiacin showed lower ED50 and stronger protective effect on infected mice than vancomycin or linezolid. Conclu-sions: Thiopeptide antibiotic nocathiacin has high antibacterial activities, which is obviously superior to vancomycin, linezolid and moxifloxacin, and there is no cross drug-resistance between them.
What problem does this paper attempt to address?